Elanco Animal Health reported $1.37 billion in sales for the first quarter of 2026, marking a 14.9% increase year-over-year [1].

The results indicate a period of accelerating growth for the NYSE-listed company as it expands its research and development investments. This momentum has led leadership to raise the company's full-year financial outlook.

Jeffrey Simmons, President, CEO and Director of Elanco, said the first quarter represents growing strength, momentum, and value. He said that the solid results and raised guidance demonstrate continued progress on the company's growth priorities.

Financial data for the quarter ended March 2026 shows the company beat previous estimates [1]. For the second quarter of 2026, the company projects revenue of $1.31 billion [1].

Looking ahead, Elanco has outlined an organic growth target of five% to seven% for the remainder of 2026 [2]. The company also provided adjusted earnings per share (EPS) guidance for the first quarter ranging from $1.03 to $1.09 [2].

To support this expansion, the company has increased its innovation target to $1.2 billion for 2026 [2]. This investment focus aims to bolster the company's pipeline of animal health products and services.

Other reports of the quarterly revenue align with these figures, citing sales of $1,371 million [3]. The company continues to operate under the leadership of Simmons as it navigates the global animal health market.

“Elanco's first quarter represents growing strength, momentum and value.”

Elanco's decision to raise both its full-year guidance and its innovation budget suggests a strategic pivot toward aggressive R&D. By targeting $1.2 billion in innovation, the company is betting that new product development will drive the 5% to 7% organic growth it seeks, moving beyond simple market recovery to active expansion in the animal health sector.